A consensus statement on the use of biosimilar medicines in hematology in Australia
Open Access
- 14 April 2020
- journal article
- review article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 16 (4) , 211-221
Abstract
Despite their availability for over a decade, the exact nature of biosimilar medicines is still poorly understood with paucity of clear treatment guidelines for their use in clinical practice in Australia. Although hematologists have had experience with biosimilars in the setting of supportive care, with the approval of the first biosimilar rituximab in hematological malignancies, it is important to revisit this topic. To inform the use of biosimilar medicines in clinical practice, we have developed a consensus statement from an Expert Panel of Australian hematologists, oncologists, and cancer pharmacists. These recommendations address the approach to use of biosimilar products in place of the corresponding reference medicine in a number of different clinical contexts. Our recommendations are based on the premise that biosimilar medicines can be considered therapeutically equivalent to their reference brand and used in a similar way to the reference product in any approved indication. We advocate for local approaches to the provision of patient information, dispensing of the intended brand and pharmacovigilance, to be developed in consultation with local hematologists and aim to improve confidence in the appropriate use of biosimilar medicines and their expected outcomes among hematologists.Keywords
This publication has 22 references indexed in Scilit:
- Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathologyBMC Medical Research Methodology, 2016
- Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documentsCurrent Medical Research and Opinion, 2016
- Physicochemical and Functional Comparability Between the Proposed Biosimilar Rituximab GP2013 and Originator RituximabBioDrugs, 2013
- The role of biosimilars in the treatment of rheumatic diseasesAnnals of the Rheumatic Diseases, 2013
- Biosimilars: what clinicians should knowBlood, 2012
- Saving money in the European healthcare systems with biosimilarsGenerics and Biosimilars Initiative Journal, 2012
- The State of the Art in the Development of BiosimilarsClinical Pharmacology & Therapeutics, 2012
- Acceptable changes in quality attributes of glycosylated biopharmaceuticalsNature Biotechnology, 2011
- Worldwide experience with biosimilar developmentmAbs, 2011
- Consensus methods: characteristics and guidelines for use.American Journal of Public Health, 1984